Smoking Status Modifies the Relationship between Th2 Biomarkers and Small Airway Obstruction in Asthma

Table 2

Baseline lung function of subjects.

Variable	Total subjects (n = 478)	Obstructive group (n = 385)	Normal group (n = 93)	value
Preinhaling short-acting bronchodilator
FVC (L)	2.91 ± 0.84	2.80 ± 0.80	3.41 ± 0.83	<0.001
FEV1 (L)	2.00 ± 0.75	1.82 ± 0.66	2.77 ± 0.63	<0.001
FEV1%pred (%)	69.48 ± 22.40	63.20 ± 18.59	95.48 ± 17.65	<0.001
FEV1/FVC (%)	67.48 ± 12.86	64.03 ± 11.50	81.80 ± 6.95	<0.001
PEF (L/s)	4.56 ± 1.92	4.15 ± 1.78	6.25 ± 1.54	<0.001
PEF%pred (%)	57.64 ± 21.75	51.97 ± 18.47	81.23 ± 18.29	<0.001
FEF50 (L/s)	1.79 ± 1.12	1.42 ± 0.82	3.30 ± 0.92	<0.001
FEF50%pred (%)	43.10 ± 24.75	34.40 ± 16.80	79.04 ± 19.30	<0.001
FEF75 (L/s)	0.66 ± 0.49	0.51 ± 0.35	1.28 ± 0.50	<0.001
FEF75%pred (%)	37.18 ± 23.32	28.62 ± 14.24	72.15 ± 20.38	<0.001
FEF25–75	1.50 ± 0.98	1.18 ± 0.70	2.84 ± 0.80	<0.001
FEF25–75%pred (%)	41.76 ± 24.73	31.91 ± 14.58	82.53 ± 14.05	<0.001
Postinhaling short-acting bronchodilator
FVC (L)	3.09 ± 0.87	2.94 ± 0.85	3.70 ± 0.70	<0.001
FEV1 (L)	2.40 ± 0.91	2.18 ± 0.82	3.32 ± 0.64	<0.001
FEV1%pred (%)	84.42 ± 30.79	76.51 ± 26.02	117.16 ± 27.25	<0.001
FEV1/FVC (%)	73.97 ± 17.35	70.05 ± 16.25	90.19 ± 11.31	<0.001
PEF (L/s)	4.80 ± 1.90	4.42 ± 1.78	6.39 ± 1.50	<0.001
PEF%pred (%)	60.97 ± 22.25	55.46 ± 19.05	83.92 ± 19.84	<0.001
FEF50 (L/s)	2.02 ± 1.15	1.66 ± 0.87	3.50 ± 0.99	<0.001
FEF50%pred (%)	49.07 ± 25.91	40.43 ± 18.11	84.72 ± 22.59	<0.001
FEF75 (L/s)	0.74 ± 0.50	0.59 ± 0.37	1.38 ± 0.49	<0.001
FEF75%pred (%)	42.94 ± 25.21	33.92 ± 16.44	79.78 ± 20.96	<0.001
FEF25–75%	1.66 ± 0.99	1.33 ± 0.70	3.01 ± 0.83	<0.001
FEF25–75%pred (%)	46.75 ± 26.48	36.67 ± 16.29	88.48 ± 18.56	<0.001

FEV1, forced expiratory volume in 1 second. FVC, forced vital capacity. PEF, peak expiratory flow. FEF, forced expiratory flow. %pred, % predicted.